FRANKFURT, May 4 (Reuters) - German drugmaker Bayer secured the rights to an experimental anti-blood-clotting drug in a deal with California-based Isis Pharmaceuticals to bolster its cardiovascular business led by blockbuster pill Xarelto.
* Says healthcare now expects sales to rise to over eur 24 billion (previously: approximately eur 23 billion)
EMEA - APAC Key Vendors - Bayer AG - F. Hoffmann-La Roche ..... Pfizer Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other ..... Allergan Inc. - Ampio Pharmaceuticals Inc. - Antisense Therapeutics
of three segments: pharmaceuticals , consumer products ..... diseases. Eye-Care Pharmaceuticals Anti-VEGF treatments ..... Regeneron 's REGN and Bayer 's BAYRY Eylea and ..... Other eye-care pharmaceuticals include treatments
the prominent players in the global home healthcare market that have been profiled in the report include 3M Health Care, Bayer AG , Abbott Laboratories, Cardinal Health, Inc., GE Healthcare, Johnson & Johnson Services, Inc., Gentiva Health Services
Companies Involved in Therapeutics Development AstraZeneca PLC Bayer AG Incuron, LLC Novartis AG Otsuka Holdings Co., Ltd. Salivary ..... AstraZeneca PLC, H2 2014 Salivary Gland Cancer - Pipeline by Bayer AG , H2 2014 Salivary Gland Cancer - Pipeline by Incuron
Nov 24 (Reuters) - Germany-based drugmaker Bayer AG is considering the sale of its diabetes device business, Bloomberg reported, citing sources.
by the drug division, Bayer reported strong third ..... expect the strong growth in pharmaceuticals sales (up 10% year over ..... growth as well. However, Bayer needs to accelerate its ..... consumer group. We believe Bayer can leverage is global
emerging-markets, reduced government budgets and increased R&D costs. For those wanting to buy, Novartis [ NVS ] and Bayer [ BAYN .ge/ BAYRY ] are attractive. Pg M7, Asia: Korean steel Posco [5490.sk/ PKX ] and Chinese car maker BYD [1211
order to acquire Cadence Pharmaceuticals . While the deal gives ..... example, we only downgraded Bayer 's BAYRY "> BAYRY issuer ..... will significantly expand Bayer 's already well-positioned ..... material science toward Bayer 's health-care operations